Drug discovery

Showing 9 of 0 results

• Effectiveness of PARP inhibitor maintenance therapy in advanced ovarian cancer by BRCA1/2 and HRD signature in real-world practice

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Comparative effectiveness
  • Drug discovery
  • Ovarian cancer
• Tumor mutational burden measurement from an FDA-approved assay and real-world overall survival on single-agent immune checkpoint inhibitors in over 8,000 patients across 24 cancer types

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Drug discovery
  • Tumor agnostic
• Metastatic patterns and outcomes by HER2 and hormone receptor status in patients with metastatic breast cancer

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Machine learning
  • Drug discovery
  • Metastatic breast cancer
  • Breast cancer
• Practice- and provider-level inequities in next-generation sequencing testing by race/ethnicity for patients with advanced non-small cell lung cancer treated in the community setting

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Health equity
  • Drug discovery
  • Non-small cell lung cancer
• Association between post-treatment alpha-fetoprotein reduction and outcomes in real-world US patients with advanced hepatocellular carcinoma

  Cancer

  • Publication summary
  • Publications
  • Drug discovery
  • Hepatocellular carcinoma
• Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy

  Blood Cancer

  • Real-world evidence
  • Publication summary
  • Publications
  • Drug discovery
  • Multiple myeloma
• Four ways biotechs can accelerate their pipeline using real-world data in 2021
  • Real-world evidence
  • Article
  • Drug discovery
• How Real-World Clinico-Genomic Data is Delivering New Cancer Insights
  • Real-world evidence
  • Article
  • Drug discovery
• Real-world outcomes of hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with high tumor mutational burden (hTMB) treated with immune checkpoint inhibitors (ICI)

  ESMO Annual Congress

  • Publications
  • Treatment patterns
  • Drug discovery
  • Metastatic breast cancer